Literature DB >> 25713779

Management of anaplastic thyroid cancer.

Xavier M Keutgen1, Samira M Sadowski1, Electron Kebebew1.   

Abstract

Anaplastic thyroid cancer (ATC) is a deadly disease with a dismal prognosis. Molecular analyses of ATC tumors have yielded interesting results, which could help in understanding the underlying mechanisms of this aggressive disease process. Managing ATC can be challenging and includes rapid diagnosis, adequate staging, and interdisciplinary, multimodal treatments to optimize patient outcome. Treatments include surgical resection to gross negative margins when possible, as well as neo- or adjuvant treatment with chemotherapy or external beam radiation (XRT) for locoregional disease. New treatment strategies include evaluating the benefits of vascular disrupting agents and tyrosine kinase inhibitors for advanced ATC with driver mutations, which can be targeted. This review summarizes key concepts in managing ATC.

Entities:  

Keywords:  Anaplastic thyroid cancer (ATC); diagnosis; prognosis; surgery; treatment

Year:  2015        PMID: 25713779      PMCID: PMC4321056          DOI: 10.3978/j.issn.2227-684X.2014.12.02

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  47 in total

1.  Prognostic factors for Korean patients with anaplastic thyroid carcinoma.

Authors:  Tae Yong Kim; Kyung Won Kim; Tae Sik Jung; Jung Min Kim; Sun Wook Kim; Ki-Wook Chung; Eun Young Kim; Gyungyub Gong; Young Lyun Oh; Soo Youn Cho; Ka Hee Yi; Won Bae Kim; Do Joon Park; Jae Hoon Chung; Bo Youn Cho; Young Kee Shong
Journal:  Head Neck       Date:  2007-08       Impact factor: 3.147

2.  Anaplastic thyroid carcinoma with osteoclast-like giant cells. A clinicopathologic, immunohistochemical, and ultrastructural study.

Authors:  M J Gaffey; E E Lack; M L Christ; L M Weiss
Journal:  Am J Surg Pathol       Date:  1991-02       Impact factor: 6.394

3.  Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period.

Authors:  O Nilsson; J Lindeberg; J Zedenius; E Ekman; J Tennvall; H Blomgren; L Grimelius; G Lundell; G Wallin
Journal:  World J Surg       Date:  1998-07       Impact factor: 3.352

4.  BRAF V600E inhibition in anaplastic thyroid cancer.

Authors:  Michael H Rosove; Parvin F Peddi; John A Glaspy
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

5.  Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma.

Authors:  Sam M Wiseman; Hamid Masoudi; Paddy Niblock; Dmitry Turbin; Ashish Rajput; John Hay; Douglas Filipenko; David Huntsman; Blake Gilks
Journal:  Am J Surg       Date:  2006-05       Impact factor: 2.565

6.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

7.  Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Authors:  Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

8.  Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.

Authors:  Jaime Miguel Pita; Inês Filipa Figueiredo; Margarida Maria Moura; Valeriano Leite; Branca Maria Cavaco
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

9.  Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Authors:  Panayiotis Savvides; Govardhanan Nagaiah; Pierre Lavertu; Pingfu Fu; John J Wright; Robert Chapman; Jay Wasman; Afshin Dowlati; Scot C Remick
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

10.  Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery.

Authors:  J Tennvall; G Lundell; P Wahlberg; A Bergenfelz; L Grimelius; M Akerman; A-L Hjelm Skog; G Wallin
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

View more
  35 in total

1.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

Review 2.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

3.  Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

Authors:  Sarika N Rao; Mark Zafereo; Ramona Dadu; Naifa L Busaidy; Kenneth Hess; Gilbert J Cote; Michelle D Williams; William N William; Vlad Sandulache; Neil Gross; G Brandon Gunn; Charles Lu; Renata Ferrarotto; Stephen Y Lai; Maria E Cabanillas
Journal:  Thyroid       Date:  2017-02-16       Impact factor: 6.568

4.  Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.

Authors:  Paul Weinberger; Sithara Raju Ponny; Hongyan Xu; Shan Bai; Robert Smallridge; John Copland; Ashok Sharma
Journal:  Thyroid       Date:  2016-12-15       Impact factor: 6.568

5.  Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism.

Authors:  Ling Ma; Honghua Fei
Journal:  J Bioenerg Biomembr       Date:  2020-02-08       Impact factor: 2.945

6.  Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer.

Authors:  Changxin Jing; Zhifei Gao; Rong Wang; Zhao Yang; Bingyin Shi; Peng Hou
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

7.  Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair.

Authors:  Ryan Robb; Linlin Yang; Changxian Shen; Adam R Wolfe; Amy Webb; Xiaoli Zhang; Marall Vedaie; Motoyasu Saji; Sissy Jhiang; Matthew D Ringel; Terence M Williams
Journal:  Clin Cancer Res       Date:  2019-05-16       Impact factor: 12.531

Review 8.  Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.

Authors:  P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré
Journal:  Clin Transl Oncol       Date:  2016-04-05       Impact factor: 3.405

9.  Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells.

Authors:  Elaheh Seyed Abutorabi; Shiva Irani; Marjan Yaghmaie; Seyed Hamid Ghaffari
Journal:  Rep Biochem Mol Biol       Date:  2020-01

10.  Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.

Authors:  Satoshi Koyama; Naritomo Miyake; Kazunori Fujiwara; Tsuyoshi Morisaki; Takahiro Fukuhara; Hiroya Kitano; Hiromi Takeuchi
Journal:  Eur Thyroid J       Date:  2018-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.